C-Suite Speaks
Chugai’s partnering office in South San Francisco advances the Japanese company’s business development activities in the US beyond its venture fund established in Boston in 2023.
Industry leaders share how Britain can strengthen its biotech ecosystem, from capital and regulation to talent and ambition, and what the sector could look like by 2030.
Praxis Precision Medicines is planning to shift from a clinical-stage company to a competitive commercial player in CNS, with the potential to launch multiple blockbuster medicines in the near future.
Surgeon burnout is not a new phenomenon, but where it once was episodic, surgeons now report that it feels more sustained. Support structures have not kept pace, said Johnson & Johnson MedTech VP Africa Wallace on the release of a new study of causes, trends and issues arising.
After nearly 30 years at NASA, Omar Hatamleh prepares for his next chapter and fourth book on AI. He told Medtech Insight AI will speed up medical breakthroughs, extend life spans and bring AGI sooner than expected but also drive job losses, erode privacy and force humans to rethink their purpose.
As biopharma continues to push the boundaries of innovation, the most powerful breakthroughs are coming from the discovery of new drug modalities, the reinvention of old ones and a strategic application of multi-modality treatment regimens.
Twenty biopharma leaders share predictions for 2026 – from shifting dealmaking dynamics and Asia's rise as an innovation epicenter to new frontiers in oncology, obesity and cell therapy, and AI's operational reckoning.
When OSE Immunotherapeutics' board ousted CEO Nicolas Poirier in October 2025, it handed his successor a clear mandate: spend less, partner sooner and stop asking shareholders to wait.
Renée Aguiar-Lucander, CEO of Hansa Biopharma, discussed the company’s leading asset, its journey toward US FDA approval and the trials and tribulations of completing a Phase III program.
Immunis's secretome therapy showed 26% gait speed improvement in sarcopenic seniors, validating a longevity platform that sidesteps FDA's refusal to recognize aging as disease.
Biogen’s president and head of North America talked to Scrip about the company’s commercial expansion into new areas in immunology and nephrology.
As the race to transform Duchenne muscular dystrophy care accelerates, Santhera Pharmaceuticals’ chief medical officer Shabir Hasham discusses how treatment is evolving, why combination therapies may define the next era and what it will take to improve life for patients and families living with DMD.
Medable pivots to agentic AI targeting clinical development's 80% manual labor bottleneck, aiming to double CRA efficiency and unlock capacity for 9,000 waiting drug candidates.
From biotech experiments to billion-dollar breakthroughs, Noubar Afeyan has built a career out of turning bold ideas into transformative companies.
Pilatus Biosciences' Switzerland-Taiwan-US structure exemplifies how biotechs might navigate US-China tensions, leveraging Chinese manufacturing efficiency while maintaining American investor credibility and partnership opportunities.
The obesity field is entering the “sobering” phase of the hype cycle; GLP-1 drugs have opened the door but have limitations. Aphaia CSO Steffen-Sebastian Bolz talks to In Vivo about shifting the focus back to patient experience, not just maximal weight loss.
Industry warns healthcare infrastructure – not manufacturing – may be the real bottleneck as cell therapies eye mass-market diseases.
In this episode of the In Vivo podcast, Kairos Pharma's chief scientific officer discusses developing therapies to reverse drug resistance in oncology, with ENV-105 showing promising Phase II results in resensitizing hormone-resistant prostate cancer.
“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.
Juby Jacob-Nara outlines her vision for expanding biosimilar uptake and leveraging policy changes to improve patient access.